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Abstract
Background Globally, over 300 million people consume di-
verse smokeless tobacco (ST) products. They are addictive,
cause cancer, increased cardiovascular mortality risks and
poor pregnancy outcomes.
Purpose of Review To identify gaps in implementing key ST
demand-reduction measures, focused literature reviews were
conducted and findings synthesized according to relevant
WHO Framework Convention on Tobacco Control (FCTC)
Articles.
Recent Findings The literature supports implementation of
ST demand-reduction measures. For taxation, labelling and
packaging, most administrations have weaker policies for ST
than cigarettes. Capacity to regulate ST contents and offer
cessation support is lacking. There is poor compliance with
bans on ST advertising, promotion and sponsorship.
Summary The literature on implementation of WHO
FCTC for ST is limited. Although strengths of ST
demand-control activities are currently identifiable from
available literature, full implementation of FCTC is lack-
ing. A wider evidence-based response to WHO FCTC is
proposed, particularly for countries facing the greatest
disease burdens.
Keywords Smokeless tobacco . Snus . Tobacco control .
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Introduction
“Smokeless tobacco” (ST) comprises tobacco products that do
not involve a combustion process, such as chewing, nasal and
oral tobacco [1•]. Globally, over 300 million people consume
ST [1•], yet ST has been largely neglected in research and
policy arenas because it is generally regarded as less harmful
than cigarettes. It is also seen as a regional rather than a global
problem, and too diverse and complex to control.
ST use is reported in at least 116 countries worldwide,
including countries in Africa, Asia, Europe and the
Americas [2•]. Smokeless tobacco consumption is therefore
a global public health issue. In many countries in South Asia,
ST is the most common form of tobacco used [3]. However,
ST products vary widely in type and composition and there
are marked regional differences in patterns of consumption.
The different products have different addictive and carcino-
genic properties. As well as nicotine, they may contain high
quantities of carcinogens, notably tobacco-specific nitrosa-
mines (TSNAs) [4] and heavy metals. pH levels vary between
products, and pH is a key determinant of absorption of harm-
ful chemicals from ST [4]. Other harmful ingredients are often
included alongside tobacco, such as areca nut, which is a
carcinogen in its own right. Consequently, there are substan-
tial differences between the health risks of different ST prod-
ucts and their associated disease-burden across different coun-
tries and regions [2•]. For example, consumption of South
Asian products (e.g. gutkha, zarda, paan, khaini) leads to a
much greater health risk than in Sweden where ST use is
equally prevalent, but the products (snus) contain much lower
levels of TSNAs (see Table 1) [4].
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ST use leads to several different types of cancer [5]. An
increased risk of cardiovascular deaths has also been reported
[6]. ST use in pregnancy is associated with low-birth weight
and stillbirths [7]. In 2010, ST use led to 1,711,539 disability
adjusted life years (DALYs) lost and 62,283 deaths due to
oral, pharyngeal and oesophageal cancers. Eighty-five per
cent of these impacts occurred in South Asians [2•].
The World Health Organization (WHO) Framework
Convention on Tobacco Control (FCTC) was enacted in
2005 [8]. This evidence-based international treaty obligates
its signatories (currently 180 countries) to implement specific
tobacco control measures. Countries implementing these mea-
sures to the highest level have seen a decline in smoking
prevalence in recent years [9]. This cannot be argued for ST,
because of several knowledge gaps [10]. Firstly, the evidence
supporting WHO FCTC measures is mostly derived from re-
search on smoked tobacco. Little is known about the transfer-
ability of these measures to ST. Secondly, while WHO reports
on the extent to which tobacco control policies are implement-
ed within member countries, there can be a lack of clarity as to
whether these policies apply to ST as well as to cigarettes.
Thirdly, where policies to control ST have been implemented,
there is little published data on their impact.
This paper investigates the extent of these knowledge gaps
for ST, in relation to the key demand-reduction measures
outlined inWHO FCTC, and proposes a policy research agen-
da to control ST.
Methods
We conducted a series of focused literature reviews, for articles
published in the English language between 2012 and 2017, on
key WHO FCTC demand-reduction measures for ST. PubMed
databaseswere searched, alongwith reference lists of all included
articles. Searches were conducted using the following keywords:
(“smokeless tobacco” OR “chewing tobacco” OR “snus” OR
“snuff”) combined with operationalised keywords for FCTC
Articles 6, 9–14 (e.g. “tax,” “price,” “content,” “disclosure,”
“packaging,” “labelling,” “warning,” “education,” “media,”
“campaign,” “marketing,” “advertising” and “cessation”). Only
studies reporting ST-specific outcomes were included, not dual
use or use of ST for harm reduction, resolving any disputes about
inclusion through discussion. A narrative synthesis of included
studies was carried out according to relevant Articles (6, 9–14) of
the Framework Convention. While assessed for potential biases,
these studies were not given any formal quality assessment
scores.
Findings
We identified 1026 citations through database searching and
screened 633 after removing duplicates. Another 467 citations
were excluded after reviewing titles and abstracts. Key rea-
sons for exclusion were papers based on product testing, harm
reduction and dual use. We conducted full-text reviews on the
remaining 166 papers and included 55 in our final narrative
synthesis. Among these, 12 papers were relevant to FCTC
Article 6 (price and taxation), 3 to Articles 9 and 10 (regula-
tion of the contents of tobacco products and their disclosures),
8 to Article 11 (packaging and labelling of tobacco products),
4 to Article 12 (education, communication, training and public
awareness), 21 to Article 13 (tobacco advertising, promotion
and sponsorship) and 7 to Article 14 (demand-reduction mea-
sures concerning tobacco dependence and cessation). Most
studies were either conducted in the USA, Nordic countries
(Sweden, Norway) or in South Asia (India, Bangladesh and
Pakistan). A range of research methods was used; however,
most studies used cross-sectional designs.
Price and Taxation
Pricing and taxation measures (FCTC Article 6) are consid-
ered the most effective demand-reduction policy tools in to-
bacco control. This also applies to ST [11].
A US-based nationally representative survey of 14–18 year
olds in 2012 highlighted that with every 10% rise in taxation,
ST consumption fell by 12–18%, at least in the short term
(consumption in the past 30 days) [12]. Referred to as price
elasticity, this drop in consumption was greater for ST (− 1.2
to − 1.8) than for cigarettes (− 0.44 to − 0.60) [12]. Four
studies from South Asia—one in youths and three in
adults—supported the above findings. Based on the Global
Youth Tobacco Survey, one study in India estimated that a
10% rise in the price of ST (gutkha) reduced its prevalence
by 5.8% [13]. Another Indian study, based on the 2009 Global
Adult Tobacco Survey, found that the total price elasticity of
Table 1 Common smokeless tobacco products
Gutkha – It is a preparation of crushed areca nut, tobacco, catechu,
paraffin wax, slaked lime and sweet or savoury flavourings. Gutkha is
consumed by placing a pinch of it between the gum and cheek and
gently sucking and chewing.
Zarda – To manufacture zarda, tobacco leaves are shredded and boiled
with lime and saffron. The mixture is then dried and mixed with finely
chopped areca nuts. It is served in paan, which is chewed and spat out.
Paan – It is a preparation combining betel leaf with areca nut and
sometimes also with tobacco. It is chewed and after chewing, it is either
spat out or swallowed.
Khaini – A commercially manufactured product that contains shredded
tobacco mixed with slaked lime, menthol and flavourings and
sometimes with areca nut. The product is kept in the mouth for 10 to
15 min and sucked from time to time.
Snus – It is produced through a heat treatment process and contains
tobacco, water, sodium carbonate, sodium chloride, moisturisers &
flavourings. For consumption, it is placed between the gum and upper
lip.
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ST demand among adult men was − 0.212, slightly lower than
that observed in youths [14]. The third study, based on the
Consumer Expenditure Survey in India, found that leaf tobac-
co (surrogate for three ST products) showed the highest price
elasticity in the poorest group (− 0.557). Hence, poor house-
holds were mostly likely to reduce ST consumption as a result
of tax rises [15]. Similarly, the International Tobacco Control
(ITC) study in Bangladesh indicated that a 10% rise in the
price of ST (zarda) would reduce its use by 6% for cheap
brands and by 4% for expensive brands [16].
Other studies have also shown similar results. A Swedish
study, based on a mathematical “SimSmoke” model, estimat-
ed that a 70% rise in ST (snus) tax could reduce its use by
11.4% by 2040; the number of ST-attributable deaths averted
between 2010 and 2040 could be up to 520 [17]. A US-based
post hoc analysis of 2003–2009 National Consumer Survey
data indicated that a tax rise could reduce ST consumption in
adults (estimated elasticity of − 0.32) [18]. These results
should be interpreted cautiously, as the study was primarily
conducted to evaluate the effect of magazine advertising on
ST use.
Where ST taxes have risen, ST sale and consumption have
fallen. In Rajasthan, India, a small regional sample of ST
vendors and consumers indicated a reduction in ST sales and
consumption following a rise in ST price [19]. However, ST
tax rises in India have been small, relative to the price in-
creases of other commodities and per capita income, indicat-
ing a rise in general affordability [20]. A tax rise in Minnesota
in 2013 resulted in price rises for ST equivalent to those for
cigarettes, although tobacco companies used promotions to
blunt the impact of taxation [21].
If tax increases are restricted to cigarettes only, there is a
potential risk of substituting ST for cigarettes. The ITC study
in Bangladesh indicated that a 10% rise in the price of ciga-
rettes without a rise in ST (zarda) price led to a 3.5% higher ST
(zarda) consumption [16]. Another study from India also
showed that a rise in bidi (cigarette) prices alone will tempt
customers to shift from bidi to ST use [15]. Similar concerns
were raised in a US-based study, which reported a 17% in-
crease in Google search queries for chewing tobacco, follow-
ing the 2009 tax rise for cigarettes, which was far greater than
that for ST [22].
Tax administration for ST is a particular challenge. In
South Asia, ST is often manufactured in small and un-
licensed units, with tax evasion and illicit trade being
common. To overcome this challenge, the Indian gov-
ernment used a presumptive taxation approach, by intro-
ducing an excise levy for ST per manufacturing ma-
chine, which increased revenue collection fourfold [1•].
Other phenomena that could undermine the public
health benefits of a tax rise on ST include unregulated
internet sale of ST (for example, bypassing EU-laws
[23]) and price promotions [21].
Regulation of the Contents of Tobacco Products and Their
Disclosures
The literature reports challenges in regulating the contents of
diverse ST products. Regulating all tobacco products for their
contents and emissions through manufacturers’ disclosures
and through regular testing and measurements are two key
provisions of the WHO FCTC Articles 9 and 10. WHO
FCTC expects its signatories to require ST manufacturers to
disclose pH levels and toxicants (TSNAs, benzo[a]pyrene and
nicotine), using recommended methods [24]. The WHO
Study Group for Tobacco Product Regulations (TobReg) rec-
ommended upper limits for TSNAs and benzo[a]pyrene for all
ST products [1•].
Currently, only nine WHO Member States regulate the
content of ST products on the market [25]. For example, the
USA requires all its STmanufacturers and importers to submit
a list of all ingredients of their products. Under US laws, the
Food and Drug Administration can establish limits on the
amounts of nicotine, toxicants and other additives in ST prod-
ucts. Sweden has established its own voluntary manufacturing
standards (for snus) called Gothiatek® [26]. These include
maximum levels for certain undesired constituents; selection
of approved raw materials, additives and flavourings;
manufacturing standards to prevent contamination and public
disclosure of all ingredients.
The South Asian and South East Asian regions where ST
products are most popular have the most diverse ST market.
However, they lack capacity to test and measure the ingredi-
ents of these products. A small step in this direction was made
in 2011, when India invoked food safety laws to ban gutkha
and tobacco-containing paan masala.
Packaging and Labelling of Tobacco Products
FCTC Article 11 ensures that the packaging and labelling of
tobacco products provide accurate information about relevant
constituents, display health warnings and do not mislead con-
sumers about a product’s characteristics and ingredients.
While considered to play a significant role in the appeal and
risk perception of ST [27], the role of packaging and labelling
has received little research attention so far. The study focus
has been on health warnings, and we found three papers based
on US-data and one from South Asia. One web-based survey
of 1000 participants, stratified according to age group, found
that health warnings and corporate branding had a significant
effect on product appeal and people’s risk perception [28].
One of the US-based studies randomised participants into
six groups and showed them graphic or text warning labels,
“FDA approved” or “low-risk” endorsement labels, no labels
or unrelated adverts on ST products [29]. Those in the graphic
warning group showed the highest levels of perceived harm.
The study recruited participants online and did not measure
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behaviour change. Based on a smaller sample of US male ST
users, one randomised controlled trial (RCT) showed that
those exposed to graphic health warning adverts were more
likely to recall messages and less likely to have tobacco crav-
ings, compared to those that saw text warnings only [30]. In a
large study in India and Bangladesh, participants were
randomised to receive either graphic pictorial warnings, sym-
bolic pictorial warnings, text-only warnings or personal testi-
monial pictorial messages on ST products [31]. The partici-
pants perceived graphic pictorial warnings as the most effec-
tive. However, despite recruiting a large sample from one
state, the study might not adequately represent the very large
and diverse population of India.
Four policy evaluation studies on ST packaging and label-
ling were found. Two were based in the USA, where a text-
only health warning appears on ST packs. The first one, based
on the 2012 National Youth Tobacco Survey (NYTS), showed
that only 40.3% of adolescents noticed any warning labels on
ST products (“most of the time” or “always”). Among those
who noticed, only a quarter thought about the serious health
risks [32]. The effect was greater among adult ST consumers.
Three quarters of those that participated in the 2012–2013
National Adult Tobacco Survey noticed the health warnings.
Among them, three-quarters thought of health risks [33]. In
India, graphic pictorial warnings replaced the symbolic scor-
pion warnings on ST products in 2011. However, these still
only covered 40% of one side of the packaging and the images
did not rotate frequently. Based on a cohort study, these
changes were neither noticed nor considered provocative
[34]. Conducted in four states on a large sample of 4733 ST
users, the study findings are generalizable. A pilot survey
among ST suppliers found that almost all ST health warnings
in Bangladesh, Nepal and Pakistan were text-only; were often
hidden, misleading, sometimes not in local languages; and did
not comply with Article 11 specifications [10].
In implementing Article 11, most signatories have set a
much lower requirement for ST than for cigarettes [1•]. A
graphic pictorial warning, covering the majority and both
sides of the packaging, and frequent rotation of images are
not required.
Education, Communication, Training and Public Awareness
Education and raising awareness of the risks associated with
consuming tobacco are important demand-reductionmeasures
(FCTC Article 12). The “SimSmoke” model predicted that,
combined with other policy measures, mass campaigning
could reduce ST consumption significantly [17]. While some
countries have launched ST awareness-raising campaigns, in-
vestment in mass media campaigns that could achieve high
levels of awareness and bring a change in the social norms is
lacking [1•]. We found two evaluations of mass campaigns
against ST. Following a 6-week mass TVand radio campaign
against ST in 2009 in India, a nationally representative large
sample of ST users reported a significant impact. More than
two thirds of ST users recalled the campaign adverts and al-
most three-quarters felt compelled to think about the health
risks. Mass campaigns through digital media can be run at low
cost and offer greater reach within a younger audience. A
process evaluation of an online media campaign
(ChewOnThis.in) showed that the campaign website had
10,949 visits and 1131 registrants in 6 weeks [35].
FCTC Article 12 requires governments to ensure that
health professionals also receive sufficient education about
ST and its associated harms. However, such awareness among
medical professionals is deficient and almost a quarter of phy-
sicians in India may advise smokers to switch from cigarettes
to ST as a “cessation aid” [36].
Tobacco Advertising, Promotion and Sponsorship
The key measure in FCTC Article 13 is a comprehensive ban
on tobacco advertising, promotion and sponsorship (TAPS).
The ban covers point of sale displays, the Internet, brand
stretching, product placement, corporate social responsibility,
and tobacco in entertainment media. Despite strict regulations,
the tobacco industry continues to invest heavily in marketing
its products, including ST. A sum of $20 million was spent on
advertising ST in the USA between June–September 2012,
mostly targeting middle-aged white men, with a strong theme
of masculinity [37]. An analysis of over 350 magazines
printed between 2005 and 2009 found 861 adverts for ST
(snuff), with more adverts for discount products targeted at
youths [38]. Web traffic on sites promoting ST (snuff) rose
between 2011 and 2014 [39]. STwas also promoted in online
video/banner tobacco adverts [40] and in YouTube videos [41,
42]. Advertising STover the Internet, in print media and at the
points of sale enhances ST curiosity [43], experimentation
[44] and uptake among youths [45, 46]. In late adolescence,
exposure to ST adverts is associated with ever ST use, and in
young adults, it is associated with regular ST use [47]. Among
general adults, such exposure increases ST consumption [14,
18, 48].
We found nine studies that assessed compliance with na-
tional policies on TAPS. The methods included consumer sur-
veys and ST supplier assessment. When asked about exposure
to any ST advertisement in the previous 6 months in a large
survey in two states in India, 74% of adults responded affir-
matively [49]. Two surveys focussed on schools; one found
that 41% of shops/stalls within 100 m of schools in India sold
ST and out of these, more than half advertised ST at point of
sale [50]. The other survey found that 54% of schools had at
least one ST advert within 100 m [51]. Self-reported ST con-
sumption among children was associated with the density of
these adverts.
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Of four US-based studies, three assessed compliance by
observing the proportion of outlets that advertised ST at point
of sale and one did so before and after the relevant FDA
regulations came into place. The first study found that 57%
of 129 tobacco outlets in Ohio displayed ST advertisements at
point of sale [52]. The next two studies found point of sale
advertising for ST in 21 and 30% of tobacco outlets, respec-
tively [53, 54]. The fourth study observed a marked reduction
in the number of advertisements at point of sale within tobacco
outlets in Ohio, following the introduction of the Tobacco
Control Act 2009 [55].
In Norway, 98% of outlets were compliant after the intro-
duction of a point of sale display ban on ST (snus) [56]. In a
pilot study comprising structured interviews with ST suppliers
in Bangladesh, Nepal and Pakistan, product display was found
to be the main form of point of sale advertisement. Also, ST
manufacturers offered promotions (bulk-buy discounts and
prize draws) to the vendors [57]. The above surveys were
limited in their generalizability and since most were conduct-
ed at one time-point, any associations cannot be extrapolated
as causal.
Demand-Reduction Measures Concerning Tobacco
Dependence and Cessation
FCTC Article 14 requires governments to promote tobacco
cessation and provide adequate support to those who are de-
pendent on tobacco and wish to quit. However, cessation sup-
port remains the most poorly implemented measure world-
wide [58]. Fewer than 50% of signatories to the WHO
FCTC have implemented Article 14 [58]. Poorer countries
have far less cessation support than high-income countries.
Most ST products contain a high nicotine concentration
[4] and regular users show strong dependency [59, 60].
Compared to smoking cessation, the evidence for ST ces-
sation is limited and complicated by ST heterogeneity [61].
A Cochrane review [62], while concluding that pharmaco-
therapies and behavioural support may help ST users to
quit, did not include any South Asian studies. The authors
recommended further research on different types of ST. ST
products in South Asia are highly alkaline, enhancing nic-
otine absorption and making them more addictive than
products used elsewhere [59]. Moreover, there is a strong
socio-cultural dimension to ST use in South Asian popula-
tions. Both factors may feature in the effectiveness of any
cessation support offered, but have rarely been considered.
Two UK non-RCTs found that behavioural support and
nicotine replacement therapy (NRT) were non-significantly
more effective than brief advice [63], and NRT predicted
short-term abstinence [64]. The latter findings were replicated
in a multi-centre cohort study across South Asia [65]. A fea-
sibility study found a culturally appropriate behaviour change
intervention was acceptable to ST users in Pakistan and the
UK [61]. One Indian RCTobserved no difference in quit rates
at 12 weeks (varenicline vs. placebo) [66], and a second
showed a small effect of a community outreach intervention
on abstinence at 6 months [67]. In the absence of RCT evi-
dence, the UK National Institute for Health and Care
Excellence (NICE) guidance [68] for ST cessation recom-
mends behavioural support only and excludes the use of phar-
macotherapies, but has recommended research to assess these.
Discussion
The primary aim of this narrative review was to identify the
published literature relating to the use of WHO FCTC
demand-reduction measures to control ST. It reports the first
overview of this issue. Although not a systematic review, clear
and pre-defined methods were followed in the conduct of this
research. Grey literature and papers not published in the
English language were omitted.
The research has established the following key findings.
Firstly, the literature is limited in content, with only 55
papers identified. Most of the identified papers reported
cross-sectional study designs, with their recognised poten-
tial for recruitment selection and recall biases and an in-
ability to establish causality. Secondly, the literature re-
ports research primarily conducted outside South Asia,
the geographic region with the highest ST prevalence and
subsequent greatest burdens on health. Thirdly, most of the
papers identified focused on WHO FCTC Article 6 (pric-
ing and taxation) and Article 13 (TAPS). In contrast, WHO
FCTC Article 14 (tobacco cessation) has been substantially
overlooked with respect to ST.
Recognising these limitations, the following substantive
findings can be cautiously proposed. Increasing ST taxa-
tion and price will reduce demand. The price elasticity of
ST is reported to be greater than smoked tobacco. Graphic
pictorial warnings on packaging, compared to other forms
of health warnings, are more effective. Implementing point
of sale regulations reduces exposure to ST advertising.
These findings are important because they demonstrate
the possibilities for ST demand-reduction measures. In the
last 10 years, WHO FCTC measures have contributed to a
substantial reduction in smoking prevalence in many coun-
tries [9]. In contrast, most countries are observed to have
either not implemented these measures for ST, or have set
standards much lower than those for cigarettes. ST taxes
have been raised, although not as much as cigarette taxes,
while health warning requirements are less strict. Other
international and regional reports have similarly identified
the challenges in regulating ST products [69•, 70].
Areas for a ST demand-reduction policy implementation
and research agenda can be identified for future action.
Ensuring and evaluating compliance with the current
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WHO FCTC Articles should be rigorous. The findings
identified from this review should be further developed,
adopting more rigorous study designs, where appropriate.
In addition, building laboratory capacity to enable further
ingredient analysis of the diverse range of ST products
should be undertaken. In turn, accurate and unambiguous
ingredient analyses can inform the robust development of
warning labels and point of sale regulation.
In conclusion, this narrative review has identified a limited
body of the literature dealing with the implementation of the
WHO FCTC with respect to ST. While most of the WHO
FCTC demand-reduction measures are applicable to ST, their
implementation is lacking compared to that for cigarettes. The
findings demonstrate some current strengths of ST demand-
control activity. A need to build upon these current strengths
and also develop a wider evidence-based response to WHO
FCTC is proposed, particularly for countries facing the
greatest disease burdens.
Compliance with Ethical Standards
Conflict of Interest Kamran Siddiqi has received research funding
through grants from the Medical Research Council, Cancer Research
UK, Pfizer and the European Union.
Aishwarya Lakshmi Vidyasagaran declares that she has no conflict of
interest.
Anne Readshaw declares that she has no conflict of interest.
Ray Croucher declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent This article
does not contain any studies with human or animal subjects per-
formed by any of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1.• National Cancer Institute. Smokeless tobacco and public health: a
global perspective. Bethesda, MD: U.S. Department of Health and
Human Services, Centers for Disease Control and Prevention and
National Institutes of Health, National Cancer Institute. 2014. This
report provides a comprehensive overview of the global chal-
lenge posed by ST, and identifies key research and policy needs.
2.• Siddiqi K, Shah S, Abbas SM,VidyasagaranA, JawadM, Dogar O,
et al. Global burden of disease due to smokeless tobacco consump-
tion in adults: analysis of data from 113 countries. BMC Med.
2015;13:194.This study presents the first estimates of the global
burden of disease due to smokeless tobacco consumption by
adults.
3. Sinha DN, Gupta PC, Ray C, Singh PK. Prevalence of smokeless
tobacco use among adults in WHO South-East Asia. Indian J
Cancer. 2012;49(4):342–6.
4. Stanfill SB, Connolly GN, Zhang L, Jia LT, Henningfield JE,
Richter P, et al. Global surveillance of oral tobacco products: total
nicotine, unionised nicotine and tobacco-specific N-nitrosamines.
Tob Control. 2011;20(3):e2-e.
5. Sinha DN, Suliankatchi RA, Gupta PC, Thamarangsi T, Agarwal
N, Parascandola M, et al. Global burden of all-cause and cause-
specific mortality due to smokeless tobacco use: systematic review
and meta-analysis. Tob Control. 2016 https://doi.org/10.1136/
tobaccocontrol-2016-053302.
6. Vidyasagaran AL, Siddiqi K, Kanaan M. Use of smokeless tobacco
and risk of cardiovascular disease: a systematic review and meta-
analysis. Eur J Prev Cardiol. 2016;23(18):1970–81.
7. Inamdar AS, Croucher RE, Chokhandre MK, Mashyakhy MH,
Marinho VC. Maternal smokeless tobacco use in pregnancy and
adverse health outcomes in newborns: a systematic review.
Nicotine Tob Res. 2015 Sep;17(9):1058–66.
8. WHO FCTC Secretariat. WHO framework convention on tobacco
control. Geneva: World Health Organization; 2003.
9. Gravely S, Giovano G, Craig L, Commar A, D’Espaignet E,
Schotte K, et al. Implementation of key demand-reduction mea-
sures of the WHO Framework Convention on Tobacco Control
and change in smoking prevalence in 126 countries: an association
study. Lancet. 2017;2:e166–74.
10. Siddiqi K, Scammell K, Huque R, Khan A, Baral S, Ali S, et al.
Smokeless tobacco supply chain in South Asia: a comparative anal-
ysis using the WHO Framework Convention on Tobacco Control.
Nicotine Tob Res. 2016 Apr;18(4):424–30.
11. Timberlake DS, Sami M, Patel S, Thiagarajan S, Badiyan R,
Willard S. The debate over weight- versus price-based taxation of
snuff in the United States’ state legislatures. J Public Health Policy.
2014;35(3):337–50.
12. Huang J, Chaloupka FJ. The impact of the 2009 Federal Tobacco
Excise tax increase on youth tobacco use. Cambridge: National
Bureau of Economic Research; 2012.
13. JosephRA, Chaloupka FJ. The influence of prices on youth tobacco
use in India. Nicotine Tob Res. 2014;16(Suppl 1):S24–9.
14. Kostova D, Dave D. Smokeless tobacco use in India: role of prices
and advertising. Soc Sci Med. 2015;138:82–90.
15. Selvaraj S, Srivastava S, Karan A. Price elasticity of tobacco prod-
ucts among economic classes in India, 2011–2012. BMJ Open.
2015;5(12):e008180.
16. Nargis N, Hussain AK, FongGT. Smokeless tobacco product prices
and taxation in Bangladesh: findings from the International
Tobacco Control Survey. Indian J Cancer. 2014;51(Suppl 1):S33–8.
17. Near AM, Blackman K, Currie LM, Levy DT. Sweden SimSmoke:
the effect of tobacco control policies on smoking and snus preva-
lence and attributable deaths. Eur J Pub Health. 2013;24(3):451–8.
18. Dave D, Saffer H. Demand for smokeless tobacco: role of advertis-
ing. J Health Econ. 2013;32(4):682–97.
19. Singh V, Sharma BB, Saxena P, Meena H, Mangal DK. Price and
consumption of tobacco. Lung India. 2012;29(3):212.
20. Rout SK, AroraM. Taxation of smokeless tobacco in India. Indian J
Cancer. 2014;51(Suppl 1):S8–12.
21. Brock B, Choi K, Boyle RG, Moilanen M, Schillo BA. Tobacco
product prices before and after a statewide tobacco tax increase. Tob
Control. 2016;25(2):166–73.
22. Jo CL, Ayers JW, Althouse BM, Emery S, Huang J, Ribisl KM. US
consumer interest in non-cigarette tobacco products spikes around
the 2009 federal tobacco tax increase. Tob Control. 2015;24(4):
395–9.
Curr Addict Rep
23. Peeters S, Gilmore AB. How online sales and promotion of snus
contravenes current European Union legislation. Tob Control.
2012;22(4):266–73.
24. WHO FCTC Secretariat. Further development of the partial guide-
lines for implementation of Articles 9 and 10 of the WHO FCTC.
Geneva: World Health Organization; 2016. Contract No.:
FCTC/COP/7/9.
25. WHO Study group on Tobacco product regulation. report on the
scientific basis of Tobacco product regulations: Fifth report of a
WHO study group. Switzerland: WHO. 2015;989:1–234.
26. Rutqvist LE, Curvall M, Hassler T, Ringberger T, Wahlberg I.
Swedish snus and the GothiaTek® standard. Harm Reduct J.
2011;8:11.
27. Liu ST, Nemeth JM, Klein EG, Ferketich AK, Kwan MP, Wewers
ME. Adolescent and adult perceptions of traditional and novel
smokeless tobacco products and packaging in rural Ohio. Tob
Control. 2014;23(3):209–14.
28. Adkison SE, Bansal-Travers M, Smith DM, O'Connor RJ, Hyland
AJ. Impact of smokeless tobacco packaging on perceptions and
beliefs among youth, young adults, and adults in the U.S: findings
from an internet-based cross-sectional survey. Harm Reduct J.
2014;11:2.
29. Popova L, Ling PM. Nonsmokers’ responses to new warning labels
on smokeless tobacco and electronic cigarettes: an experimental
study. BMC Public Health. 2014;14:997.
30. Klein EG, Quisenberry AJ, Shoben AB, Cooper S, Ferketich
AK, Berman M, et al. Health warning labels for smokeless
tobacco: the impact of graphic images on attention, recall,
and craving. Nicotine Tob Res. 2017:ntx021. https://doi.org/
10.1093/ntr/ntx021.
31. Mutti S, Reid JL, Gupta PC, Pednekar MS, Dhumal G, Nargis N,
et al. Perceived effectiveness of text and pictorial health warnings
for smokeless tobacco packages in Navi Mumbai, India, and
Dhaka, Bangladesh: findings from an experimental study. Tob
Control. 2016;25(4):437–43.
32. Johnson SE, Wu CC, Coleman BN, Choiniere CJ. Self-reported
exposure to tobacco warning labels among U.S. middle and high
school students. Am J Prev Med. 2014;47(2 Suppl 1):S69–75.
33. Agaku IT, Singh T, Rolle IV, Ayo-Yusuf OA. Exposure and re-
sponse to current text-only smokeless tobacco health warnings
among smokeless tobacco users aged ≥ 18years, United States,
2012–2013. Prev Med. 2016;87:200–6.
34. Gravely S, Fong GT, Driezen P, Xu S, Quah AC, Sansone G, et al.
An examination of the effectiveness of health warning labels on
smokeless tobacco products in four states in India: findings from
the TCP India cohort survey. BMC Public Health. 2016;16(1):
1246.
35. Hamill S, Turk T, Murukutla N, Ghamrawy M, Mullin S. I ‘like’
MPOWER: using Facebook, online ads and new media to mobilise
tobacco control communities in low-income and middle-income
countries. Tob Control. 2015;24(3):306–12.
36. Panda R, Persai D, Mathur M, Sarkar BK. Perception and practices
of physicians in addressing the smokeless tobacco epidemic: find-
ings from two states in India. Asian Pac J Cancer Prev. 2013;14(12):
7237–41.
37. Richardson A, Ganz O, Stalgaitis C, Abrams D, Vallone D.
Noncombustible tobacco product advertising: how companies are
selling the new face of tobacco. Nicotine TobRes. 2014;16(5):606–
14.
38. Timberlake DS, Pechmann C. Trends in the use and advertising of
discount versus premium snuff. Nicotine Tob Res. 2013;15(2):474–
81.
39. Timberlake DS, Bruckner TA, Ngo V, Nikitin D. The reach and
impact of direct marketing via brand websites of moist snuff. Tob
Regul Sci. 2016;2(2):153–65.
40. Richardson A, Ganz O, Vallone D. Tobacco on the web: surveil-
lance and characterisation of online tobacco and e-cigarette adver-
tising. Tob Control. 2015;24(4):341–7.
41. Seidenberg AB, Rodgers EJ, Rees VW, Connolly GN. Youth ac-
cess, creation, and content of smokeless tobacco (“dip”) videos in
social media. J Adolesc Health. 2012;50(4):334–8.
42. Bromberg JE, Augustson EM, Backinger CL. Portrayal of smoke-
less tobacco in YouTube videos. Nicotine Tob Res. 2012;14(4):
455–62.
43. Portnoy DB, Wu CC, Tworek C, Chen J, Borek N. Youth curiosity
about cigarettes, smokeless tobacco, and cigars: prevalence and
associations with advertising. Am J Prev Med. 2014;47(2 Suppl
1):S76–86.
44. Agaku IT, Ayo-Yusuf OA. The effect of exposure to pro-tobacco
advertising on experimentation with emerging tobacco products
among U.S. adolescents. Health Educ Behav. 2014;41(3):275–80.
45. Sardana M, Goel S, Gupta M, Sardana V, Singh BS. Is exposure to
tobacco advertising, promotion and sponsorship associated with
initiation of tobacco use among current tobacco users in youth in
India? Asian Pac J Cancer Prev: Apjcp. 2015;16(15):6299–302.
46. Doku D, Koivusilta L, Raisamo S, Rimpela A. Tobacco use and
exposure to tobacco promoting and restraining factors among ado-
lescents in a developing country. Public Health. 2012;126(8):668–
74.
47. Timberlake DS. Advertising receptivity and youth initiation of
smokeless tobacco. Subst Use Misuse. 2016;51(9):1077–82.
48. Sinha DN, Palipudi KM, Oswal K, Gupta PC, Andes LJ, Asma S.
Influence of tobacco industry advertisements and promotions on
tobacco use in India: findings from the Global Adult Tobacco
Survey 2009–2010. Indian J Cancer. 2014;51(Suppl 1):S13–8.
49. Bansal-Travers M, Fong GT, Quah AC, Sansone G, Pednekar MS,
Gupta PC, et al. Awareness of pro-tobacco advertising and promo-
tion and beliefs about tobacco use: findings from the Tobacco
Control Policy (TCP) India Pilot Survey. J Epidemiol Glob
Health. 2014;4(4):303–13.
50. Balappanavar AY, Mohanty V, Hussain A. Compliance with tobac-
co promotion and sale laws in school neighbourhoods in India.
Asian Pac J Cancer Prev: APJCP. 2017;18(2):563.
51. Mistry R, Pednekar M, Pimple S, Gupta PC, McCarthy WJ, Raute
LJ, et al. Banning tobacco sales and advertisements near education-
al institutions may reduce students’ tobacco use risk: evidence from
Mumbai, India. Tob Control. 2015;24(e1):e100–7.
52. Frick RG, Klein EG, Ferketich AK, Wewers ME. Tobacco adver-
tising and sales practices in licensed retail outlets after the Food and
DrugAdministration regulations. J Community Health. 2012;37(5):
963–7.
53. Widome R, Brock B, Klein EG, Forster JL. Smokeless tobacco
advertising at the point of sale: prevalence, placement, and demo-
graphic correlates. Nicotine Tob Res. 2012;14(2):217–23.
54. Roberts ME, Berman ML, Slater MD, Hinton A, Ferketich AK.
Point-of-sale tobacco marketing in rural and urban Ohio: could
the new landscape of tobacco products widen inequalities? Prev
Med. 2015;81:232–5.
55. Klein EG, Ferketich AK, Abdel-Rasoul M, Kwan M-P, Kenda L,
Wewers ME. Smokeless tobacco marketing and sales practices in
Appalachian Ohio following federal regulations. Nicotine Tob Res.
2012;14(7):880–4.
56. Scheffels J, Lavik R. Out of sight, out of mind? Removal of point-
of-sale tobacco displays in Norway. Tob Control. 2012;22(e1):e37–
42.
57. Siddiqi K, Scammell K, Huque R, Khan A, Baral S, Ali S,
et al. Smokeless tobacco supply chain in South Asia: a
compara t ive ana lys i s us ing the WHO Framework
Convention on Tobacco control. Nicotine Tob Res.
2016;18(4):424–30.
Curr Addict Rep
58. Nilan K, RawM, McKeever TM, Murray RL, McNeill A. Progress
in implementation of WHO FCTC Article 14 and its guidelines: a
survey of tobacco dependence treatment provision in 142 countries.
Addiction. 2017. https://doi.org/10.1111/add.13903.
59. Huque R, Shah S, Mushtaq N, Siddiqi K. Determinants of salivary
cotinine among smokeless tobacco users: a cross-sectional survey
in Bangladesh. PLoS One. 2016;11(8):e0160211.
60. Mushtaq N, Beebe LA, Vesely SK. Determinants of salivary cotin-
ine concentrations among smokeless tobacco users. Nicotine Tob
Res. 2012;14(10):1229–34.
61. Siddiqi K, Dogar O, Rashid R, Jackson C, Kellar I, O’Neill N, et al.
Behaviour change intervention for smokeless tobacco cessation: its
development, feasibility and fidelity testing in Pakistan and in the
UK. BMC Public Health. 2016;16(1):501.
62. Ebbert JO, Elrashidi MY, Stead LF. Interventions for smokeless
tobacco use cessation. Cochrane Database of Systematic Reviews.
Cochrane Database Syst Rev. 2015; (10). Art. No.: CD004306.
https://doi.org/10.1002/14651858.CD004306.pub5.
63. Croucher R, Islam S, Jarvis MJ, Garrett M, Rahman R, Shajahan S,
et al. Oral tobacco cessation with UK resident Bangladeshi women:
a community pilot investigation. Health Educ Res. 2003;18(2):
216–23.
64. Croucher R, Shanbhag S, Dahiya M, Kassim S, McNeill A.
Predictors of successful short-term tobacco cessation in UK
resident female Bangladeshi tobacco chewers. Addi (Abingdon,
England). 2012;107(7):1354–8.
65. Croucher R, Shanbhag S, Dahiya M, Kassim S, Csikar J, Ross L.
Smokeless tobacco cessation in South Asian communities: a multi-
centre prospective cohort study. Addiction. 2012; 107 (S2):45–52.
66. Jain R, Jhanjee S, Jain V, Gupta T,Mittal S, Goelz P, et al. A double-
blind placebo-controlled randomized trial of varenicline for smoke-
less tobacco dependence in India. Nicotine Tobacco Res: Off J Soc
Res Nicotine Tobacco. 2014;16(1):50–7.
67. Sarkar BK, West R, Arora M, Ahluwalia JS, Reddy KS, Shahab L.
Effectiveness of a brief community outreach tobacco cessation in-
tervention in India: a cluster-randomised controlled trial (the
BABEX Trial). Thorax. 2017;72(2):167–73.
68. National institute for health and care excellence. Smokeless tobac-
co: South Asian communities London: NICE; available at http://
guidance.nice.org.uk/PH39 (2012). Accessed 10 August 2017.
69.• Khan A, Huque R, Shah SK, Kaur J, Baral S, Gupta PC, et al.
Smokeless tobacco control policies in South Asia: a gap analysis
and recommendations. Nicotine Tob Res. 2014;16(6):890–4. This
study documents wide gaps in implementing ST policy in high-
burden countries of South Asia.
70. Siddiqi K, Gupta PC, Prasad VM, Croucher R, Sheikh A.
Smokeless tobacco use by south Asians. The Lancet Glob Health.
2013;1(2):e71.
Curr Addict Rep
